377 related articles for article (PubMed ID: 12788569)
1. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
Jong P; Yusuf S; Rousseau MF; Ahn SA; Bangdiwala SI
Lancet; 2003 May; 361(9372):1843-8. PubMed ID: 12788569
[TBL] [Abstract][Full Text] [Related]
2. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
[TBL] [Abstract][Full Text] [Related]
3. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
[TBL] [Abstract][Full Text] [Related]
4. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
Parker AB; Yusuf S; Naylor CD
Am Heart J; 2002 Dec; 144(6):941-7. PubMed ID: 12486418
[TBL] [Abstract][Full Text] [Related]
5. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
Dries DL; Exner DV; Gersh BJ; Domanski MJ; Waclawiw MA; Stevenson LW
J Am Coll Cardiol; 1998 Sep; 32(3):695-703. PubMed ID: 9741514
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
[TBL] [Abstract][Full Text] [Related]
7. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Szucs TD; Goedde M; Berger K; Kiowski W
Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
[TBL] [Abstract][Full Text] [Related]
8. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
Vermes E; Ducharme A; Bourassa MG; Lessard M; White M; Tardif JC;
Circulation; 2003 Mar; 107(9):1291-6. PubMed ID: 12628950
[TBL] [Abstract][Full Text] [Related]
9. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.
Alsheikh-Ali AA; Wang PJ; Rand W; Konstam MA; Homoud MK; Link MS; Estes NA; Salem DN; Al-Ahmad AM
Am Heart J; 2004 Jun; 147(6):1061-5. PubMed ID: 15199356
[TBL] [Abstract][Full Text] [Related]
10. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
Exner DV; Dries DL; Domanski MJ; Cohn JN
N Engl J Med; 2001 May; 344(18):1351-7. PubMed ID: 11333991
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.
Al-Khadra AS; Salem DN; Rand WM; Udelson JE; Smith JJ; Konstam MA
J Am Coll Cardiol; 1998 Feb; 31(2):419-25. PubMed ID: 9462588
[TBL] [Abstract][Full Text] [Related]
13. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial.
Ahn SA; Jong P; Yusuf S; Bangdiwala SI; Pouleur HG; Rousseau MF
J Am Coll Cardiol; 2006 May; 47(9):1904-5. PubMed ID: 16682319
[No Abstract] [Full Text] [Related]
14. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators.
Rogers WJ; Johnstone DE; Yusuf S; Weiner DH; Gallagher P; Bittner VA; Ahn S; Schron E; Shumaker SA; Sheffield LT
J Am Coll Cardiol; 1994 Feb; 23(2):393-400. PubMed ID: 8294693
[TBL] [Abstract][Full Text] [Related]
15. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.
Exner DV; Dries DL; Waclawiw MA; Shelton B; Domanski MJ
J Am Coll Cardiol; 1999 Mar; 33(4):916-23. PubMed ID: 10091816
[TBL] [Abstract][Full Text] [Related]
16. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
Konstam MA; Kronenberg MW; Rousseau MF; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
Circulation; 1993 Nov; 88(5 Pt 1):2277-83. PubMed ID: 8222122
[TBL] [Abstract][Full Text] [Related]
17. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
[TBL] [Abstract][Full Text] [Related]
18. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
Konstam MA; Rousseau MF; Kronenberg MW; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
Circulation; 1992 Aug; 86(2):431-8. PubMed ID: 1638712
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Anker SD; Negassa A; Coats AJ; Afzal R; Poole-Wilson PA; Cohn JN; Yusuf S
Lancet; 2003 Mar; 361(9363):1077-83. PubMed ID: 12672310
[TBL] [Abstract][Full Text] [Related]
20. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial.
Glick H; Cook J; Kinosian B; Pitt B; Bourassa MG; Pouleur H; Gerth W
J Card Fail; 1995 Dec; 1(5):371-80. PubMed ID: 12836712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
